New partnership to build advanced predictive testing for blood cancer multiple myeloma
(RCSI) By combining genomic testing and next generation sequencing technology, a new partnership led by RCSI researchers aims to advance predictive tests for multiple myeloma (MM), the second most common blood cancer in Ireland. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 17, 2020 Category: Cancer & Oncology Source Type: news

Genomic Profiling Detects Smoldering Multiple Myeloma Risk Genomic Profiling Detects Smoldering Multiple Myeloma Risk
Could genomic profiling accurately predict which patients with smoldering multiple myeloma are at risk for progression? Find out what there is to know.Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 15, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Multiple Myeloma: Types of Treatment
Title: Multiple Myeloma: Types of TreatmentCategory: Diseases and ConditionsCreated: 9/9/2020 12:00:00 AMLast Editorial Review: 9/9/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - September 9, 2020 Category: Cancer & Oncology Source Type: news

Team approach at Atrium Health saved man ’s life when his situation became dire
Jack Wheeler has lived with multiple myeloma – a blood cancer – for 20 years. But after developing troubling symptoms that quickly got worse, Wheeler ended up hospitalized – in the middle of the COVID-19 pandemic. Quick intervention from an interdisciplinary team across Atrium Health Carolinas Medical Center and Atrium Health Levine Canc er Institute saved his life. Wheeler is now in remission from his cancer and continuing his treatment in a promising clinical trial. Read more about Jack… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 1, 2020 Category: Biotechnology Authors: Atrium Health Source Type: news

ICER assessing CAR-T cell therapies for multiple myeloma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - September 1, 2020 Category: Drugs & Pharmacology Source Type: news

FDA approves carfilzomib and daratumumab with dexamethasone for multiple myeloma
On August 20, 2020, the Food and Drug Administration approved carfilzomib (KYPROLIS, Onyx Pharmaceuticals, Inc.) and daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received one to three lines o (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 21, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 21, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

RVD Induction Therapy in Newly Diagnosed Multiple Myeloma RVD Induction Therapy in Newly Diagnosed Multiple Myeloma
What benefits might be achieved with a combination lenalidomide, bortezomib, and dexamethasone induction regimen in patients with multiple myeloma?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 17, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

How Long a Person Can Live With Multiple Myeloma?
Title: How Long a Person Can Live With Multiple Myeloma?Category: Procedures and TestsCreated: 8/14/2020 12:00:00 AMLast Editorial Review: 8/14/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 14, 2020 Category: Cancer & Oncology Source Type: news

Is Multiple Myeloma Cancer Curable?
Title: Is Multiple Myeloma Cancer Curable?Category: Procedures and TestsCreated: 8/14/2020 12:00:00 AMLast Editorial Review: 8/14/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 14, 2020 Category: Cancer & Oncology Source Type: news

New radiotracer increases multiple myeloma survival
A new alpha-radioimmunotherapy agent, Pb-212-anti-CD38, prevented tumor growth...Read more on AuntMinnie.comRelated Reading: Whole-body DWI-MRI could aid treatment of myeloma SNMMI touts radioimmunotherapy study C-11 methionine PET aids diagnosis of adenomas, multiple myeloma ARRS: Low-dose CT beats x-ray for multiple myeloma (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 12, 2020 Category: Radiology Source Type: news

FDA Approves Belantamab in R/R Multiple Myeloma FDA Approves Belantamab in R/R Multiple Myeloma
The first-in-class drug belantamab mafodotin (Blenrep) has been approved in the United States for use in relapsed and refractory multiple myeloma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 6, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Blenrep (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
London UK 05 August 2020 -- GlaxoSmithKline announced the US Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 5, 2020 Category: Drugs & Pharmacology Source Type: news

NHS England spends £160m on new 'Covid-friendly' cancer drugs
Patients to be given treatments less likely to damage immune system and in some cases able to be taken at homeNHS England is spending £160m on new “Covid-friendly” cancer drugs that will be less likely to damage the immune system and, in some cases, can be taken at home so that patients do not have to visit hospital.NHS England said 2,000 patients had already benefitted from a range of treatments approved for use as “swaps” for existing drugs. More will be available from this week, after a series of deals struck between the NHS and pharma companies, it said in a statement.Some of these new opt...
Source: Guardian Unlimited Science - August 3, 2020 Category: Science Authors: Sarah Boseley Health editor Tags: NHS Cancer Society Health Cancer research Medical research Science UK news Coronavirus outbreak Source Type: news

Scottrade founder Rodger Riney gives Emory University's Winship Cancer Institute $7.8M
Emory University's Winship Cancer Institute said Thursday it's received a gift of $7.8 million from the Paula and Rodger Riney Foundation to fund multiple myeloma research. The two-year project will support fast-tracked research projects at Winship in multiple myeloma, a blood cancer caused by malignant plasma cells that accumulate in the bone marrow. Rodger Riney founded Scottrade Financial Services, which was acquired in 2017 by TD Ameritrade in a $4 billion deal . He was diagnosed with multiple… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 30, 2020 Category: Pharmaceuticals Authors: David Allison Source Type: news

Drug Trials Snapshots: DARZALEX
DARZALEX is a drug used to treat patients with a form of blood cancer called multiple myeloma. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 29, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

A safer cell therapy harnesses patient T cells to fight multiple myeloma
(American Association for the Advancement of Science) A treatment for multiple myeloma that harnesses the body's cancer-fighting T cells was safe in humans and showed preliminary signs of effectiveness, according to a clinical trial involving 23 patients with relapsed or treatment-resistant disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 29, 2020 Category: International Medicine & Public Health Source Type: news

Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple Myeloma
PRINCETON, N.J.,& CAMBRIDGE, Mass.-- July 29, 2020 -- (BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced the submission of their Biologics License Application (BLA) to the U.S. Food and Drug... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - July 29, 2020 Category: Drugs & Pharmacology Source Type: news

EU Gives Thumb Up for Belantamab in R/R Multiple Myeloma EU Gives Thumb Up for Belantamab in R/R Multiple Myeloma
The first-in-class drug belantamab mafodotin (Blenrep) has been recommended for conditional approval in Europe for use in relapsed and refractory multiple myeloma.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 24, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Fox Chase and Ben-Gurion University receive cancer treatment study grant
(American Associates, Ben-Gurion University of the Negev) The research focus is to test the effectiveness of an immune-stimulating antibody developed by BGU researcher Angel Porgador, PhD, to attack multiple myeloma, a blood cell tumor localized in the bone marrow. The antibody helps the immune system kill multiple myeloma tumor cells. Since it may work on many different types of tumors, future research will explore its use as a wide-ranging treatment option for patients with cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 17, 2020 Category: Cancer & Oncology Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic...
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

Belantamab for MM: Benefit Outweighs Ocular Risk, FDA Panel Says Belantamab for MM: Benefit Outweighs Ocular Risk, FDA Panel Says
FDA advisers welcomed the prospect of a new drug for relapsed and refractory multiple myeloma (MM) but stressed the need for an REMS program to manage belantamab's risk to eyes.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 15, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we are pleased to welcome a guest post from Chris Arendt, Ph.D., a leader of Takeda’s oncology team to discuss how the company is ensuring cancer research and medicines continue to benefit patients in the age of COVID-19.“The new normal” has been used to describe the challenging and dy...
Source: The Catalyst - June 24, 2020 Category: Pharmaceuticals Authors: Guest Contributor Tags: PhRMA Member Company Cancer Coronavirus Source Type: news

Blood cancer symptoms: Swelling in this part of the body could be a warning sign
BLOOD CANCER - there are three main types: leukaemia, lymphoma and myeloma. Those with non-Hodgkin lymphoma may experience swelling, but where in the body? (Source: Daily Express - Health)
Source: Daily Express - Health - June 18, 2020 Category: Consumer Health News Source Type: news

Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, NJ, June 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumab[i] in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare and potentially fatal disease.[1],[2] The data demonstrated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a higher hematologic complete response rate (CR), (53 percent vs. 18 percent [P
Source: Johnson and Johnson - June 15, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Meletios A. Dimopoulos, MD, on the Phase III BOSTON Study in Multiple Myeloma
Meletios A. Dimopoulos, MD, discussed the phase III Boston study examining a new combination therapy to treat patients with multiple myeloma who have received 1 to 3 prior therapies. (Source: CancerNetwork)
Source: CancerNetwork - June 8, 2020 Category: Cancer & Oncology Authors: Meletios A. Dimopoulos, MD Source Type: news

Belantamab Mafodotin Triplet Yields Promising Clinical Benefit in Relapsed/Refractory Multiple Myeloma
The combination use of belantamab mafodotin plus bortezomib   and dexamethasone induced high clinical benefit rates and a tolerable safety profile in patients with relapsed or refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 8, 2020 Category: Cancer & Oncology Authors: Lisa Astor Source Type: news

JNJ-4528 Continues to Show Durable Responses in Relapsed/Refractory Multiple Myeloma
The CAR T-cell therapy continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2020 Category: Cancer & Oncology Authors: Tony Berberabe, MPH Source Type: news

Ide-cel Appears Active in Almost Three-Fourths of Heavily Pretreated Patients with Myeloma
The BCMA-targeting CAR T-cell therapy yielded a response in73% of patients with heavily pretreated relapsed/refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2020 Category: Cancer & Oncology Authors: Jason M. Broderick Source Type: news

CC-92480 Plus Dexamethasone Shows Favorable Activity in Relapsed/Refractory Myeloma
CC-92480 in combination with dexamethasone demonstrated favorable activity and safety data in patients with heavily pretreated relapsed or refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2020 Category: Cancer & Oncology Authors: Dylann Cohn-Emery Source Type: news

Parameswaran Hari, MD, MRCP, Discusses Lenalidomide Maintenance Outcomes in Multiple Myeloma
Parameswaran Hari, MD, MRCP, discussed the progression-free survival of patients who stopped versus continued lenalidomide maintenance therapy to treat multiple myeloma from a follow-up trial presented at the 2020 ASCO Virtual Scientific Program. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2020 Category: Cancer & Oncology Authors: Parameswaran Hari, MD, MRCP Source Type: news

Belantamab Mafodotin Shows Promising Response in Relapsed/Refractory Multiple Myeloma
Belantamab mafodotin monotherapy induced durable responses and appeared to be well tolerated   in patients with heavily pretreated relapsed or refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2020 Category: Cancer & Oncology Authors: Brittany Lovely Source Type: news

ASCO Expert Discusses Clinical Benefit of Combination for Relapsed/Refractory Multiple Myeloma
Ajay K. Nooka, MD, MPH, FACP discussed the clinical benefits of belantamab mafodotin in combination with bortezomib/dexamethasone to treat multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2020 Category: Cancer & Oncology Authors: Ajay K. Nooka, MD Source Type: news

Cost of care for multiple myeloma in Oncology Care Model
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2020 Category: Drugs & Pharmacology Source Type: news

Teclistamab Shows Promise for Patients with Relapsed/Refractory Myeloma
Teclistamab appeared to be a safe and efficacious treatment for patients with relapsed/refractory multiple myeloma, according to a phase I study presented at the ASCO Virtual Scientific Program. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Brielle Benyon Source Type: news

Pack Health partners with California university for pilot program on myeloma
Pack Health is participating in a pilot study with the University of California San Francisco Helen Diller Family Comprehensive Cancer Center. For Pack Health, it's the latest in a series of notable partnerships for the Birmingham-based firm. The study intends to use digital coaching to support individuals with multiple myeloma who are undergoing stem cell transplantation.  “We are excited to expand the role of digital coaching to this unique patient population for whom the transplantation… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 29, 2020 Category: Pharmaceuticals Authors: Tyler Patchen Source Type: news

Pack Health partners with California university for pilot program on myeloma
Pack Health is participating in a pilot study with the University of California San Francisco Helen Diller Family Comprehensive Cancer Center. For Pack Health, it's the latest in a series of notable partnerships for the Birmingham-based firm. The study intends to use digital coaching to support individuals with multiple myeloma who are undergoing stem cell transplantation.  “We are excited to expand the role of digital coaching to this unique patient population for whom the transplantation… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 29, 2020 Category: Biotechnology Authors: Tyler Patchen Source Type: news

Addition of Selinexor to Bortezomib, Dexamethasone Improves Responses in Myeloma
The addition of selinexor, a selective inhibitor of nuclear export, to bortezomib and dexamethasone improved progression-free survival across all subgroups in a study of pretreated patients with multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Beth Fand Incollingo Source Type: news

Carfilzomib Triplet Therapy Shows Inferior PFS in Newly Diagnosed Multiple Myeloma
Carfilzomib combined with lenalidomide and dexamethasone failed to improve progression-free survival, compared with the current standard of care triplet of bortezomib, lenalidomide, and dexamethasone, in patients with newly diagnosed multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Jessica Skarzynski Source Type: news

Colorado tool, My-DST, may pick best multiple myeloma treatment
(University of Colorado Anschutz Medical Campus) Response of liquid biopsies to approved drugs can help show resistance, predict response. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 28, 2020 Category: Cancer & Oncology Source Type: news

Carfilzomib does not improve outcomes in newly diagnosed myeloma compared to bortezomib
(ECOG-ACRIN Cancer Research Group) The combination of carfilzomib, lenalidomide, and dexamethasone (KRd) did not improve progression-free survival in patients with newly diagnosed myeloma absent a high-risk disease prognosis, compared with the standard of care -- bortezomib, lenalidomide, and dexamethasone (VRd). The data from a planned interim analysis for the ENDURANCE (E1A11) randomized phase three trial will be presented at the ASCO 2020 plenary. KRd had more severe cardiac, pulmonary, and renal toxicities. Neuropathy was more common among those receiving VRd. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 28, 2020 Category: International Medicine & Public Health Source Type: news

Myeloma cells shift osteoblastogenesis to adipogenesis by inhibiting the ubiquitin ligase MURF1 in mesenchymal stem cells
The suppression of bone formation is a hallmark of multiple myeloma. Myeloma cells inhibit osteoblastogenesis from mesenchymal stem cells (MSCs), which can also differentiate into adipocytes. We investigated myeloma-MSC interactions and the effects of such interactions on the differentiation of MSCs into adipocytes or osteoblasts using single-cell RNA sequencing, in vitro coculture, and subcutaneous injection of MSCs and myeloma cells into mice. Our results revealed that the α4 integrin subunit on myeloma cells stimulated vascular cell adhesion molecule–1 (VCAM1) on MSCs, leading to the activation of protein ki...
Source: Signal Transduction Knowledge Environment - May 26, 2020 Category: Science Authors: Liu, Z., Liu, H., He, J., Lin, P., Tong, Q., Yang, J. Tags: STKE Research Articles Source Type: news

Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller
SAN FRANCISCO, May 21, 2020 -- (Healthcare Sales & Marketing Network) -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational de... Biopharmaceuticals, Oncology, Personnel Sutro Biopharma, XpressCF+, multiple myeloma, non-Hodgkin lymphom (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 21, 2020 Category: Pharmaceuticals Source Type: news

Christopher R. Flowers, MD, on Disparities in Lymphoma and Myeloma
The lymphoma and myeloma expert indicated that one of the key ways to address these disparities in lymphoma and myeloma is to improve minority and rural accrual in clinical trials. (Source: CancerNetwork)
Source: CancerNetwork - May 21, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Johnson & Johnson to Provide Webcast Fireside Chat on Clinical Data to be Presented at the American Society of Clinical Oncology and the Janssen Oncology Strategy and Portfolio
New Brunswick, NJ (May 18, 2020) – The Janssen Pharmaceutical Companies of Johnson & Johnson will participate in a pre-recorded fireside chat webcast hosted by Cantor Fitzgerald focused on clinical data being presented at the virtual 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. The webcast is intended for investors and other interested parties, and will be available beginning at 8:00a.m ET on Tuesday, May 19, 2020.The webcast will feature Peter F. Lebowitz, MD, PhD, Global Therapeutic Area Head, Oncology, Janssen Research & Development, LLC, who will highlight key clinical data including ...
Source: Johnson and Johnson - May 18, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Saad Z. Usmani, on the Approval of Daratumumab and Hyaluronidase-fihj
The hematologist and medical oncologist discussed the approval of daratumumab and hyaluronidase-fihj for use in adult patients with newly diagnosed or relapsed/refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - May 18, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Approves Pomalidomide for Kaposi Sarcoma FDA Approves Pomalidomide for Kaposi Sarcoma
Pomalidomide is the first new treatment option for Kaposi sarcoma in more than 20 years; the drug is already marketed for multiple myeloma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 15, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Venetoclax/carfilzomib/dexamethasone in Refractory MM Venetoclax/carfilzomib/dexamethasone in Refractory MM
This report documents treatment of two refractory patients with a novel therapeutic combination.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 15, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Coronavirus US: Drug for rare bone marrow cancer tested
Researchers say selinexor, which is currently approved treat multiple myeloma, blocks a protein that allows coronavirus to multiply in our cells and plays a role in the inflammatory response. (Source: the Mail online | Health)
Source: the Mail online | Health - May 14, 2020 Category: Consumer Health News Source Type: news

Janssen ’s BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-4528, an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy in the treatment of patients with relapsed or refractory multiple myeloma. Longer-term follow-up results from the Phase 1b portion of the study (n=29), to be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #8505), show t...
Source: Johnson and Johnson - May 14, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news